Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR

• Four oral sessions to be presented, including validation data for Shield MCD test, selected for highly anticipated NCI Vanguard Study
• 18 total abstracts to showcase significant developments in multiomic profiling with liquid and tissue biopsies across screening, recurrence monitoring and treatment selection

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present 18 abstracts, including four oral sessions, showcasing advances in multi-cancer detection and multiomic precision oncology testing enabled by its Guardant Infinity™ smart liquid biopsy platform at the 2025 American Association for Cancer Research (AACR) Annual Meeting, April 25-30 in Chicago.

Key data that will be highlighted include:

• An oral presentation of performance data for the Shield™ MCD test, selected for the National Cancer Institute’s Vanguard Study evaluating emerging multi-cancer detection (MCD) technology
• Additional oral presentations on methylation-based cancer signal of origin identification, methylation profiling for lung cancer subtyping, and a real-world data analysis of BRAF mutations in non-small cell lung cancer
• Analytical validation of Guardant’s new tissue profiling assay with integrated multiomics, showing a high success rate with minimal tissue input and supporting the acceleration of novel biomarker discovery
• New methylation-based applications for liquid biopsy, including molecular subtyping of lung and breast cancer, rule-out of actionable genomic mutations, and identification of promoter methylation and MTAP deletions

“We look forward to sharing new data demonstrating the tremendous potential of the Guardant Infinity smart liquid biopsy platform to provide researchers and healthcare providers with a more complete picture of cancer, including genomics, epigenomics and more,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “This multidimensional view of cancer biology is enabling advances in precision oncology ranging from blood-based multi-cancer detection to identification of novel biomarkers that can help bring the next generation of cancer therapeutics to patients sooner.”

The full abstracts for Guardant Health and a list of all abstracts being presented at AACR 2025 can be found on the AACR website.

For information and updates from the conference, follow Guardant Health on LinkedIn, X (Twitter) and Facebook or visit AACR booth #1523.

Full List of Guardant Health Presentations
Date and Time (CDT)	Title	Abstract and Poster Section/Board	Guardant Product
Multi-Cancer
Sunday, April 27, 2:00-5:00pm	Analytical validation of a tissue-free epigenomic assay for circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection in early-stage cancer	Abstract #692 Poster Section 29 Poster Board #25	Guardant Reveal™
Sunday, April 27, 2:00-5:00pm	Development and characterization of a negative prediction algorithm for actionable mutations utilizing genomic and epigenomic profiling in cfDNA	Abstract #733 Poster Section 31 Poster Board #18	Guardant Infinity
Sunday, April 27, 3:00-5:00pm	A novel methylation-based classifier to identify cancer signal of origin using blood-based testing	Oral Minisymposium Session Abstract #6365	Guardant Infinity Screening
Monday, April 28, 9:00am-12:00pm	Inferring immune and tissue cell type contributions to cell-free DNA (cfDNA) with a DNA methylation assay	Abstract #1951 Poster Section 28 Poster Board #19	Guardant Infinity
Monday, April 28, 9:00am-12:00pm	Detection of clinically actionable somatic variants in post-operative samples from patients with molecular residual disease	Abstract #1953 Poster Section 28 Poster Board #21	Guardant Reveal
Monday, April 28, 9:00am-12:00pm	Blood-based mapping of the personalized tumor epigenomic landscape	Abstract #1955 Poster Section 28 Poster Board #23	Guardant Infinity
Monday, April 28, 2:00-5:00pm	Analytical validation of cancer gene promoter methylation detection in cfDNA liquid biopsy assay	Abstract #3255 Poster Section 29 Poster Board #20	Guardant Infinity
Tuesday, April 29, 2:30-4:30pm	Evaluation of a plasma cell-free DNA methylation-based multi-cancer detection test	Oral Minisymposium Session Abstract #6425	Shield MCD Test
Tuesday, April 29, 2:00-5:00pm	A tumor-specific, methylation-based algorithm to identify MTAP gene deletions via tissue-free circulating tumor DNA	Abstract #5924 Poster Section 30 Poster Board #16	Guardant Infinity
Tuesday, April 29, 2:00-5:00pm	Analytical validation of a robust, integrated multiomics tissue assay powered by the Guardant Infinity platform	Abstract #5935 Poster Section 30 Poster Board #27	Guardant Infinity
Tuesday, April 29, 2:00-5:00pm	Landscape of epigenomic tumor fraction in large pan-cancer cfDNA cohort	Abstract #5936 Poster Section 30 Poster Board #28	Guardant Infinity
Wednesday, April 30, 9:00am-12:00pm	Analytical validation of a new plasma-only bioinformatics classifier to identify variants from clonal hematopoiesis (CH) in cfDNA liquid biopsy assays	Abstract #6603 Poster Section 9 Poster Board #10	Guardant Infinity
Lung
Sunday, April 27, 3:00-5:00pm	Non-invasive cell free DNA (cfDNA) methylation profiling for accurate proportional quantification of lung cancer subtypes	Oral Minisymposium Session Abstract #1142	Guardant Infinity
Tuesday, April 29, 9:00am-12:00pm	EGFR PACC mutations occur more frequently as compound mutations with better responses to EGFR TKIs	Abstract #4594 Poster Section 30 Poster Board #14	Guardant360®
Tuesday, April 29, 2:30-4:30pm	Unveiling the potent anti-tumor activity and underlying mechanism of action of the novel pan-RAF inhibitor exarafenib in BRAF-mutated NSCLC	Oral Minisymposium Session Abstract #6389	Guardant Inform™
Breast
Monday, April 28, 2:00-5:00pm	Pre- and post-operative analysis of circulating tumor DNA in patients with breast cancer treated with neoadjuvant therapy using a tissue-free, methylation-based approach	Abstract #3360 Poster Section 32 Poster Board #30	Guardant Reveal
Monday, April 28, 2:00-5:00pm	Liquid based methylation profiling for quantification of breast cancer subtypes	Abstract #3247 Poster Section 29 Poster Board #12	Guardant Infinity
Colorectal
Monday, April 28, 9:00am-12:00pm	Employing joint modeling to support clinical interpretation of ctDNA dynamics during the treatment of advanced colorectal cancer	Abstract #2481 Poster Section 41 Poster Board #2	Guardant Inform

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250422372352/en/

Investor Contact:

Zarak Khurshid

investors@guardanthealth.com

Media Contact:

Michael Weist

press@guardanthealth.com

+1 317-371-0035

Source: Guardant Health, Inc.

FAQ

What major developments will Guardant Health (GH) present at AACR 2025?

Guardant Health will present 18 abstracts, including 4 oral sessions, focusing on Shield MCD test validation data, methylation-based cancer detection, and advances in liquid and tissue molecular profiling.

How does Guardant Health's Shield MCD test contribute to cancer detection?

The Shield MCD test, selected for the NCI's Vanguard Study, will present performance data for multi-cancer detection using blood-based testing technology.

What are the key applications of Guardant Health's liquid biopsy platform?

The Guardant Infinity platform enables multi-cancer detection, molecular subtyping of lung and breast cancer, identification of promoter methylation, and MTAP deletions through blood-based testing.

What new validation data will GH present for tissue profiling?

GH will present analytical validation of a new tissue profiling assay with integrated multiomics, demonstrating high success rates with minimal tissue input and supporting novel biomarker discovery.

What cancer types are covered in Guardant Health's AACR 2025 presentations?

The presentations cover multiple cancer types including lung cancer, breast cancer, and colorectal cancer, with applications in screening, recurrence monitoring, and treatment selection.